![Angion](/api/images/company-pic/0-508564-company.png)
Contactez-nous
À propos de la société
Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass. It was founded in 1998 and is based in Uniondale, New York.
US
Inconnue
Entreprise non vérifiée
Transparence commerciale
- Informations sur l'entreprise non vérifiées
- Demandez à leurs clients des avis
- N'a pas répondu aux avis négatifs